InsiderSignal.AI

InsiderSignal.ai

ALT - Altimmune, Inc.

Insider Purchase by Gill John (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Gill John, serving as Dir at Altimmune, Inc. (ALT), purchased 9,200 shares at $3.41 per share, for a total transaction value of $31,350.00. Following this transaction, Gill John now holds 21,700 shares of ALT.

This purchase represents a 74.00% increase in Gill John's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 6, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, meaning the disclosure happened on the same day as the trade.

Altimmune, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Gill John

Gill John

Dir

John M. Gill, age 73, is an independent Director at Altimmune, Inc. (NASDAQ: ALT), having served on the board since August 2004 (originally with PharmAthene prior to the 2017 merger).[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill)[[3]](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000046/alt-20250925xdef14a.htm)[[5]](https://altimmune.com/team/john-m-gill/) He serves on the Audit Committee (designated as the financial expert) and the Nominating & Corporate Governance Committee, contributing his deep expertise in financial oversight, biopharma operations, and board governance.[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill)[[3]](https://www.sec.gov/Archives/edgar/data/1326190/000132619025000046/alt-20250925xdef14a.htm) A Certified Public Accountant (CPA) with a B.A. in Accounting and Economics from Rutgers University, Gill also served in the U.S. Marine Corps.[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill) His career highlights include co-founding TetraLogic Pharmaceuticals (2003–2013, as President, CEO, and Director), serving as President and CEO of PharmAthene, Inc. (2015–2017 until the Altimmune merger), and senior roles at 3-Dimensional Pharmaceuticals (EVP, COO, Director; acquired by Johnson & Johnson in 2003) and SmithKline Beecham/GlaxoSmithKline (R&D executive and finance positions).[[1]](https://fintool.com/app/research/companies/ALT/people/john-gill)[[4]](https://uk.marketscreener.com/insider/MACK-GILL-A04G88/)[[5]](https://altimmune.com/team/john-m-gill/) Recently, on December 23, 2025, Gill purchased 12,500 shares of Altimmune stock at $4.10 per share, owning approximately 12,500 shares with an estimated net worth tied to these holdings of at least $48,250.[[6]](https://www.gurufocus.com/insider/26934/john-gill)[[8]](https://www.marketbeat.com/instant-alerts/john-gill-acquires-12500-shares-of-altimmune-nasdaqalt-stock-2025-12-23/)

View full insider profile →

Trade Price

$3.41

Quantity

9,200

Total Value

$31,350.00

Shares Owned

21,700

Trade Date

Monday, April 6, 2026

1 days ago

SEC Filing Date

Monday, April 6, 2026

HEALTHCAREBIOTECHNOLOGY

About Altimmune, Inc.

Company Overview

No company information available
View news mentioning ALT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5419852

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime